

NOTE: This order is nonprecedential.

**United States Court of Appeals
for the Federal Circuit**

REGENERON PHARMACEUTICALS, INC.,
Plaintiff-Appellee

v.

**MYLAN PHARMACEUTICALS INC., BIOCON
BIOLOGICS INC.,**
Defendants-Appellants

**AMGEN USA, INC., CELLTRION, INC., SAMSUNG
BIOEPIS CO., LTD., FORMYCON AG, AMGEN INC.,**
Defendants

2024-2002

Appeal from the United States District Court for the Northern District of West Virginia in Nos. 1:22-cv-00061-TSK-JPM, 1:23-cv-00089-TSK-JPM, 1:23-cv-00094-TSK-JPM, 1:23-cv-00097-TSK-JPM, 1:23-cv-00106-TSK-JPM, 1:24-cv-00039-TSK-JPM, 1:24-cv-00053-TSK, 1:24-md-03103-TSK-JPM, Chief Judge Thomas S. Kleeh.

O R D E R

The parties, having so agreed,

IT IS ORDERED THAT:

2

REGENERON PHARMACEUTICALS, INC. v. MYLAN
PHARMACEUTICALS INC.

The above-captioned appeal is dismissed under Fed. R.
App. P. 42(b) with each side to bear their own costs.

FOR THE COURT

April 16, 2025
Date



Jarrett B. Perlow
Clerk of Court

ISSUED AS A MANDATE: April 16, 2025